Drug
Aqw051
Aqw051: highest development phase Phase 2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| AQW051 2 mg (single and multiple doses) NCT01163227 | Phase 2 | Schizophrenia Disorders |
Latest
No recent events.
Follow Aqw051 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.